Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis

Abstract

Introduction: Corticosteroid-induced osteoporosis (CIO) is the most common type of secondary osteoporosis, leading to fractures, and increased morbidity and mortality. Source of data: Pubmed, EMBASE, Scopus and Google Scholar databases. Areas of agreement: Prolonged glucocorticoids administration leads to secondary osteoporosis. Areas of controversy: The optimal management for CIO is controversial. Growing points: The present study compared bone mineral density, fractures and adverse events in patients undergoing treatment with risedronate, alendronate, zoledronate, denosumab or etidronate for CIO. Areas timely for developing research: For selected patients with CIO, alendronate performed better overall. These results must be interpreted within the limitations of the present study. Level of evidence: I, Bayesian network meta-analysis of randomized clinical trials.